P16 Methylation as an Early Predictor for Cancer Development From Oral Epithelial Dysplasia: A Double-blind...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• P16 gene silencing via methylation or deletion is a frequent early event in cancer.
• Oral epithelial dysplasia (OED) is a precancerous condition with varying malignant potential.

Purpose of the Study:

• To prospectively evaluate P16 methylation as an early predictor of oral cancer development in patients with OED.
• To assess the diagnostic accuracy of P16 methylation for identifying malignant potential in OED.

Main Methods:

• A prospective, double-blind, multicenter cohort study involving 181 patients with mild or moderate OED.
• P16 methylation analysis using the MethyLight assay.
• Minimum 3-year follow-up to monitor OED progression and cancer development.

Main Results:

• Of 152 informative cases, 21 patients (14.3%) developed OED-derived squamous cell carcinoma during follow-up (median 41 months).
• P16 methylation-positive patients had a significantly higher cancer progression rate (27.1%) compared to methylation-negative patients (8.1%; adjusted OR=4.6, P=0.006).
• P16 methylation demonstrated a sensitivity of 62% and specificity of 76% for predicting cancer development from OED.

Conclusions:

• P16 methylation is a reliable biomarker for assessing the malignant potential of oral epithelial dysplasia.
• This finding supports the use of P16 methylation testing for early oral cancer risk stratification.